Two cases of Immune Thrombocytopenia (ITP) related to viral vector vaccination ChAdOx1-S (AstraZeneca) and a good response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy

---

Konstantina Salveridou
 

Bethesda Hospital, Germany

: J Womens Health, Issues Care

Abstract

---

Background: In 2019, a new coronavirus disease emerged in Wuhan, China, known as SARS-COV-2, severe acute respiratory syndrome coronavirus 2, and caused an ongoing pandemic. Symptomatology of the syndrome is variable, with complications extending to hematopoiesis and hemostasis. Approximately a year after onset of the virus, four vaccination formulas became available to the public, based on a viral vector or mRNA technology. These vaccine formulas have been hampered with hematological complications, like vaccine-induced immune thrombotic thrombocytopenia (VITT) and vaccine-related ITP (immune thrombocytopenic purpura). ITP is a disease with autoimmune pathogenesis characterized by antibody production against platelets and an increased hemorrhagic risk. A decent number of cases have been referred to as possible adverse effects of COVID-19 vaccinations. Case presentation: In this case report, we present two cases of newly diagnosed ITP after vaccination with ChAdOx1-S (AstraZeneca), with a good response to treatment with thrombopoietin-receptor agonists (TPO-RAs). Discussion: we observed an absence of response after corticosteroids and IVIG therapy and a positive therapeutic outcome on TPO-RA. Conclusions: in the ongoing pandemic, there is an urgent need to create therapeutic guidelines for vaccination-related clinical entities and to clarify indications for the vaccination of patients with preexisting hematological diseases.

Biography

---

Konstantina Salveridou has completed her PhD from Ruhr University Bochum, Germany. Currently, she is senior consultant in department of Hematology,Oncology and Palliative Medicine in Bethesda Hospital, Mönchengladbach, Germany. She presented papers in several national and international conferences.